Recently, the American Congress of Oncology (#ASCO18) was held in Chicago where the latest advances in #coloncancer , research, through #immunotherapy were presented. Various studies have been carried out on different immunotherapeutic drugs that have given very promising results.
There are currently two immunotherapeutic drugs (Pembrolizumab y Nivolumab) approved for colon cancer caused by a genetic mutation called Microsatellite instability; that cause a deficiency in the DNA repairing mechanisms and therefore there are a greater number of mutations. Although this mutation is not very common (15% of the total number of cases and 4% of the patients in advanced stages) it is important to carry out a study in all patients, given that the subgroup may benefit from such an effective treatment.
June 5, 2018
Read other news
Online appointment and download of test results through My HC.
Tel.: +34 952 908 628
952908898 Oncology
951829978 Diagnosis by imaging
951829947 Gynecology
952908897 Fertility
951829947 Physiotherapy